Bladder Cancer mRNA Subtype Characterization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and treating muscle-invasive bladder cancer and metastatic bladder cancer are inadequate, as they fail to accurately stratify patient responses to therapeutic treatments, leading to poor prognosis for 25% of patients.
Innovation Solution
Characterizing bladder cancer through mRNA-based expression subtypes, including luminal, luminal-papillary, luminal-infiltrated, basal-squamous, and neuronal markers, to tailor treatment approaches, such as using checkpoint inhibitors, tyrosine kinase inhibitors, and immune checkpoint therapies based on specific marker expressions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mRNA-based expression subtyping is implemented to stratify patient responses, then treatment efficacy and prognosis are improved, but device complexity and measurement precision requirements increase
Solution Approach 1:
The patent segments bladder cancer into five distinct mRNA expression subtypes (luminal-papillary, luminal-infiltrated, luminal, basal-squamous, and neuronal) based on molecular profiles. This segmentation allows for stratified treatment approaches tailored to each subtype, improving patient prognosis while using standardized qRT-PCR measurement systems that are not excessively complex.
2Measurement precision
If multiple marker detections are performed to characterize bladder cancer subtypes, then measurement precision is improved, but loss of time and productivity decrease
Solution Approach 1:
The patent combines the detection of multiple mRNA markers (including luminal markers like UPK2, UPK1A, FOXA1, GATA3; basal-squamous markers like CD44, KRT5, KRT6A, KRT14; and other subtype-specific markers) into a single qRT-PCR assay panel. This merging approach enables simultaneous characterization of multiple cancer subtypes with high measurement precision while minimizing the time required compared to performing separate assays for each marker.
Data Source
AI summary
The present invention features methods for characterizing mutational profiles in patients with bladder cancer.